Numerai GP LLC Sells 32,921 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Numerai GP LLC cut its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 58.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,845 shares of the company's stock after selling 32,921 shares during the quarter. Numerai GP LLC's holdings in PROCEPT BioRobotics were worth $1,920,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC raised its position in PROCEPT BioRobotics by 11.9% during the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Perpetual Ltd acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth $66,972,000. Wellington Management Group LLP lifted its holdings in PROCEPT BioRobotics by 38.8% during the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares during the period. Vanguard Group Inc. raised its position in shares of PROCEPT BioRobotics by 6.1% during the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after acquiring an additional 297,075 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of PROCEPT BioRobotics in the fourth quarter worth approximately $22,422,000. 89.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PRCT. Bank of America dropped their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Truist Financial reduced their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Finally, Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $90.00.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. Company insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Price Performance

PRCT traded up $0.61 on Monday, reaching $58.68. The company had a trading volume of 166,174 shares, compared to its average volume of 814,785. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -30.07 and a beta of 1.10. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The business has a 50 day simple moving average of $55.22 and a 200 day simple moving average of $71.77.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. During the same period in the previous year, the firm posted ($0.51) earnings per share. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. As a group, sell-side analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).